Literature DB >> 2225420

The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease).

J W Olin1, J R Young, R A Graor, W F Ruschhaupt, J R Bartholomew.   

Abstract

Between 1970 and 1987, 112 patients were diagnosed as having thromboangiitis obliterans (TAO). The age was 42 +/- 11 years (mean +/- SD; range, 20-75 years); 23% were women, and 7% were more than 60 years old when they were first diagnosed. Ischemic ulcerations were present in 85 (76%) patients: 24 (28%) patients with upper-extremity, 39 (46%) patients with lower-extremity, and 22 (26%) patients with both upper- and lower-extremity lesions. Ninety-one (81%) patients had rest pain, 49 (44%) patients had Raynaud's phenomenon, and 43 (38%) patients had superficial thrombophlebitis. We were able to follow up 89 of the 112 (79%) patients for 1-460 months (mean follow-up time, 91.6 +/- 84 months). Sixty-five (73%) patients had no amputations, while 24 (27%) had one or more of the following amputations: finger, six (15%) patients; toe, 13 (33%) patients; transmetatarsal, four (10%) patients; below knee, 14 (36%) patients; and above knee, two (5%) patients. Forty-three (48%) patients stopped smoking for a mean of 80 +/- 105 months (median, 46.5 months; range, 1-420 months), and only two (5%) patients had amputations after they stopped smoking, while 22 (42%) patients had amputations while continuing to smoke (p less than 0.0001). The spectrum of patients with TAO is changing in that the male-to-female ratio is decreasing (3:1), more older patients are being diagnosed, and upper-extremity involvement is commonly present. In the 48% of patients who stopped smoking, amputations and continued disease activity were uncommon.

Entities:  

Mesh:

Year:  1990        PMID: 2225420

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Distribution of arterial involvement in thromboangiitis obliterans (Buerger's disease): results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan.

Authors:  S Sasaki; M Sakuma; T Kunihara; K Yasuda
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Thromboangiitis Obliterans (Buerger's Disease).

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

3.  Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors.

Authors:  Kyung-Bok Lee; Eun-Suk Kang; Ae-Kyeong Kim; Min-Hee Kim; Young-Soo Do; Kwang-Bo Park; Hong-Suk Park; Soong Ho Um; Seung-Woo Cho; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2011-11       Impact factor: 2.500

4.  Decrease in the incidence of Buerger's disease recurrence in northern Thailand.

Authors:  Kamphol Laohapensang; Kittipan Rerkasem; Vinaisak Kattipattanapong
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report.

Authors:  Joaquin De Haro; Aurora Florez; Jose Luis Fernandez; Francisco Acin
Journal:  BMJ Case Rep       Date:  2009-05-12

6.  [Necrosis with mummification of the foot in a 33-year-old man with anxiety disorder].

Authors:  D Zajonz; N von der Höh; M Moche; T Lingscheidt; C Josten; C-E Heyde; U J A Spiegl
Journal:  Chirurg       Date:  2017-08       Impact factor: 0.955

7.  Thromboangitis Obliterans involving Bilateral Upper limb Extremities - A Rare Case Report from Malaysia.

Authors:  Uthamalingam Murali; Mohammad Azhar Anis Ahmad; Fatin Najihah
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

9.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

10.  Buerger's disease: a multidisciplinary diagnostic and therapeutic challenge.

Authors:  Nassim Parvizi; Joseph Shalhoub; Alun H Davies
Journal:  JRSM Short Rep       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.